We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Roche Holdings Ltd AG (QX) | USOTC:RHHBY | OTCMarkets | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 29.83 | 30.16 | 30.20 | 121 | 13:39:54 |
From May 2022 to May 2024
Biogen Inc. said the U.S. Food and Drug Administration has accepted its application seeking approval of BIIB800, a proposed biosimilar to Actemra. "Biogen: FDA Accepts Application for Actemra Biosimilar," at 7:50 a.m. ET, incorrectly said the European Medicines Agency had accepted the application.
(END) Dow Jones Newswires
December 09, 2022 09:26 ET (14:26 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Roche (QX) Chart |
1 Month Roche (QX) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
